<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422682</url>
  </required_header>
  <id_info>
    <org_study_id>TCD11484</org_study_id>
    <secondary_id>20060102</secondary_id>
    <nct_id>NCT00422682</nct_id>
  </id_info>
  <brief_title>A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1B, Open-Label, Dose Escalation Study Evaluating the Safety of BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety and establish the maximum tolerated dose
      (MTD) of the combination of BSI-201 with chemotherapeutic regimens in adult subjects with
      histologically or cytologically documented advanced solid tumors.

      Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess
      characteristics typical of the PARP inhibitor class. The exact mechanism has not yet been
      fully elucidated, however based on experiments on tumor cells performed in the laboratory,
      iniparib is a novel investigational anti-cancer agent that induces gamma-H2AX (a marker of
      DNA damage) in tumor cell lines, induces cell cycle arrest in the G2/M phase in tumor cell
      lines, and potentiates the cell cycle effects of DNA damaging modalities in tumor cell lines.
      Investigations into potential targets of iniparib and its metabolites are ongoing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and efficacy</measure>
    <time_frame>ongoing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate (CR + PR)</measure>
    <time_frame>every 2 cycles</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BSI-201 + topotecan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BSI-201 + temozolomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bsi-201 + gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bsi-201 + carboplatin/paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bsi-201 + topotecan</intervention_name>
    <description>21 day cycle</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bsi-201 + temozolomide</intervention_name>
    <description>28 day cycle</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bsi-201 + gemcitabine</intervention_name>
    <description>28 day cycle</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bsi-201 + carboplatin/paclitaxel</intervention_name>
    <description>21 day cycle</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years old with a histologically or cytologically documented, advanced solid tumor

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1

          -  Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (without granulocyte colony-stimulating
             factor [G-CSF] support within 2 weeks of study day 1); platelet count ≥ 100.0 x 10^9/L
             (without transfusion within 2 weeks of study day 1); and hemoglobin ≥ 9.0 g/dL
             (erythropoietic agents allowed)

          -  At least a 14-day period from end of last dose of chemotherapy received

          -  Any prior toxicity from prior chemotherapeutic treatment recovered to ≤ grade 1

        Exclusion Criteria:

          -  Subject enrolled in another investigational device or drug trial, or is receiving
             other investigational agents

          -  Hematological malignancies

          -  Symptomatic or untreated brain metastases requiring concurrent treatment, inclusive of
             but not limited to surgery, radiation, and corticosteroids.

          -  History of seizure disorder

          -  Myocardial infarction (MI) within 6 months of study day 1, unstable angina, congestive
             heart failure (CHF) with New York Heart Association (NYHA) &gt; class II, or uncontrolled
             hypertension

          -  Concurrent or prior (within 7 days of study day 1) anticoagulation therapy (low dose
             for port maintenance allowed)

          -  Specified concomitant medications

          -  Serum creatinine &gt; 1.5 x upper limit of normal (ULN)

          -  Elevated liver enzymes (AST/ALT) &gt; 2.5 x ULN, or &gt; 5.0 x ULN if secondary to liver
             metastases; alkaline phosphatase &gt; 2.5 x ULN or &gt; 5.0 x ULN if secondary to liver or
             bone metastases; total bilirubin &gt; 1.5 x ULN

          -  Radiation therapy within 14 days of study day 1

          -  Antibody therapy for the treatment of an underlying malignancy within 14 days of study
             day 1

          -  Concurrent radiation therapy is not permitted throughout the course of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2007</study_first_submitted>
  <study_first_submitted_qc>January 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2007</study_first_posted>
  <last_update_submitted>June 9, 2016</last_update_submitted>
  <last_update_submitted_qc>June 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Iniparib</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

